The analyst at Thomas Weisel who covers Amylin Pharma (AMLN) is out with comments this afternoon concerning the company's Byetta diabetes medication. TWPT believes that IMS scrip data is showing sales of the drug (a derivative of gila monster saliva) are light for the 1st quarter. TWPT estimates sales of as low as $142 mln vs consensus estimates of $149 mln.
Personal experience: I am a severe diabetic. I can look at something sweet and my blood sugar level will go up (ok, that's exaggerating a bit). I tried Byetta for a while and it does lower blood glucose levels - just 10 units does the trick with that stuff. BUT it also can come with the side effect of severe nausea. I knew I had to stop using Byetta when I was driving out to Hershey, PA last fall and almost without warning had to pull the car off to the shoulder on I-78 and dash out and throw up over the guard rail, while the kids looked back and watched and my wife rolled her eyes and shook her head. LOL.